Serum BDNF levels before and after the development of mood disorders: a case-control study in a population cohort. by Ihara, K et al.
OPEN
ORIGINAL ARTICLE
Serum BDNF levels before and after the development of mood
disorders: a case–control study in a population cohort
K Ihara1,9, H Yoshida2,9, PB Jones3, M Hashizume4, Y Suzuki5, H Ishijima6, HK Kim2, T Suzuki7 and M Hachisu8
Serum levels of brain-derived neurotrophic factor (BDNF) are low in major depressive disorder (MDD), and were recently shown to
decrease in chronic depression, but whether this is a trait or state marker of MDD remains unclear. We investigated whether serum
BDNF levels decrease before or after the developments of MDD and other mood disorders through a case–control study nested in a
cohort of 1276 women aged 75–84 years in 2008. Psychiatrists using the Structured Clinical Interview for DSM-IV identified incident
cases of mood disorders at follow-up surveys in 2010 and 2012: 28 of MDDs, 39 of minor depressive disorders (minDDs) and 8 of
minor depressive episodes with a history of major depressive episodes (minDEs with MDE history). A total of 106 representative
non-depressed controls were also identified in the 2012 follow-up. We assayed BDNF levels in preserved sera of cases and controls
at baseline and at follow-up. Serum BDNF levels at baseline in cases of MDD, minDD or minDE with MDE history were no lower than
those in controls. The decrease in the serum BDNF level from baseline to follow-up was greater in cases of MDD or minDE with MDE
history than in controls or cases of minDD. These results show that serum BDNF levels are not a trait marker of MDD in old women
but appeared to be a state marker. The different changes in BDNF levels among diagnostic groups suggest that MDD has a
pathophysiologic relation to minDE with MDE history, rather than to minDD.
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INTRODUCTION
Brain-derived neurotrophic factor (BDNF) has critical roles in
neural proliferation, growth and survival, and in nearly all aspects
of neural circuit function.1 It is prevalent in the limbic region and
prefrontal cortex, which are key areas related to mood.
Postmortem studies have shown that cerebral BDNF is associated
with major depressive disorder (MDD)2–4 and may be decreased in
patients with depression. Furthermore, BDNF is peripherally
abundant, and its serum levels are low in patients with MDD5,6
but can be increased with antidepressant therapy.6–8 Thus, BDNF
is a possible biomarker of MDD.
Before clinical studies of BDNF, animal studies showed that
BDNF expression in the hippocampus, frontal cortex and other
regions of the brain is decreased by stress,9,10 that the decrease of
BDNF is reversed by antidepressants treatment10 and that BDNF
has antidepressant-like effects.11 The understanding of intracel-
lular signaling has been increased, such as by the finding that
upregulation of cyclic adenosine monophosphate response
element-binding protein is related to the increase of BDNF in
mood-related regions of the brain.12
By combining the evidence from neurophysiological studies
with evidence from studies of morphological alterations caused by
stress in animal brains,13–15 and by associating the morphological
alteration to the decreased volume of the hippocampus in
patients with MDD,16,17 Duman et al.18 proposed the neurotrophin
hypothesis, in which BDNF is involved in the pathophysiology of
depression. Subsequently, the hypothesis was further developed19
by evidence from the earlier studies of the postmortem cerebral
and peripheral blood.2–8
The neurotrophin hypothesis is strongly supported by clinical
evidence.20–27 A large-scale meta-analysis of patients with MDD
has shown low serum levels of BDNF.28 However, the hypothesis
remains challenged by several issues.29 One issue is the causal
relationship between lower serum levels of BDNF and the
development of MDD:19,28,29 is serum BDNF a trait marker30–34
or a state marker33,35,36 of MDD? Although most evidence relies on
cross-sectional data, Bus et al.36 provided strong longitudinal
evidence for a state marker showing a decrease of serum BDNF in
chronic MDD. However, they did not control the effect of a history
of MDD and they did not show the decrease in incident MDD.
Whether serum BDNF is a trait or state marker of incident MDD
remains unclear. To investigate whether serum BDNF levels
decease before or after the development of MDD and other
mood disorders, we longitudinally examined serum BDNF levels in
cases and controls of mood disorders derived from a population
cohort in which we considered the effect of MDD history.
MATERIALS AND METHODS
This was a case–control study in a cohort from which serum was preserved.
The original cohort comprised 1289 participants of a baseline survey in
October and November 2008, which targeted 10 948 women, aged 75–84
years, in Itabashi Ward, Tokyo. After excluding 13 persons (11 persons with
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MDD and 2 persons with dementia) identified through a baseline
psychiatric evaluation, we established a new cohort of 1276 subjects.
Two follow-up surveys were performed in October 2010 and October 2012.
Each survey of the cohort was performed at the Tokyo Metropolitan
Institute of Gerontology. Survey periods were 14, 12 and 9 days in 2008,
2010 and 2012, respectively. The survey consisted of physical and
psychological examinations and questionnaires that included a self-
administered depression scale37 referred to in Japan as the Depression
Scale Basic Checklist (DSBC). The total score of the DSBC is 0–5 points and
when 2 or more points is the cutoff for screening depression in the elderly.
Subjects suspected with the DSBC in 2008, 2010 or 2012 to have
depression were asked to undergo a psychiatric evaluation. We also asked
subjects not suspected of having depression to undergo psychiatric
evaluation. They were from two samples: a convenient sample38 chosen
from participants in the 2010 follow-up and a consecutive one comprising
participants on 3.5 days of all survey periods in the 2012 follow-up.
Psychiatric evaluation was performed within 2 months after each survey.
Psychiatrists used the mood episodes (A) module and optional disorders
(J3 and J4) module of the Structured Clinical Interview for DSM-IV (SCID)39
and identified mood disorders during the past 1 month and previous life.
As the SCID requires psychiatrists to identify the onset time of disorders,
we could identify incident cases of mood disorders that developed
between the baseline survey and follow-up surveys, excluding cases that
suffered from MDD at baseline. In addition to mood disorders according to
the Diagnostic and Statistical Manual of Mental Disorders, fourth edition
(DSM-IV),40 incident cases could include minor depressive disorder
(minDD) according to the criteria sets for further study in DSM-IV.41 We
also included depression that meets the criteria for minDD except that
there had never been a major depressive episode (MDE) or a dysthymic
disorder (referred to as ‘minor depressive episode (minDE)’), as minDE is
often treated in the same way as minDD, without being distinguished from
it. The SCID also enabled us to identify the status, including current, full
remission, partial remission or under treatment, of the mood disorders at
the surveys when blood was drawn to preserve samples of serum. The
GRID–Hamilton Rating Scale for Depression (HAMD)42 was used to assess
all cases of mood disorders identified with the SCID, and subjects who
scored 6 or fewer points on the HAMD were ultimately judged to not have
any mood disorder, except for those who were judged to be in remission
or partial remission of a mood disorder. We excluded persons from cases if
they had taken any antidepressant at baseline. Subjects who were found in
the 2012 survey to have no previous or current mood disorder and to have
no antidepressant use in their lives comprised a control group. Subjects
with 23 points or less on the Mini-Mental State Examination43 were not
included in either the mood disorder groups or the control group.
Blood samples were stored at − 80 °C. Serum collected in 2012 was
assayed with an enzyme-linked immunosorbent assay in February or
March 2013. The serum stored since 2010 for cases of mood disorders
found in 2010 and serum stored since 2008 for all cases and controls were
assayed in February through April 2014. Serum BDNF levels were measured
with the BDNF Emax ImmunoAssay System (Promega, Madison, WI, USA),
according to the manufacturer’s instructions. In short, 96-well microplates
were coated with anti-BDNF monoclonal antibody and incubated
overnight at 4 °C. The microplates were incubated in a blocking buffer
for 1 h at room temperature. The samples, which were diluted 50 times
with assay buffer, and BDNF standard were placed in the microplates
at room temperature under conditions of horizontal shaking for 2 h, and
were washed with a buffer containing Tris-buffered saline and Tween 20.
The microplates were incubated with antihuman BDNF polyclonal
antibody at room temperature for 2 h and washed with the buffer. The
microplates were then incubated with anti-immunoglobulin Y antibody
conjugated to horseradish peroxidase for 1 h at room temperature,
washed with the buffer and incubated for 10 min adding with peroxidase
substrate of tetramethylbenzidine solution to induce a color reaction. The
reaction was stopped with 1 N HCl. The absorbance at 450 nm was
measured with an automated microplate reader. All measurements were
performed in duplicate. The BDNF standard curve was linear from 7.8 to
500 pg ml− 1, and the detection limit was 10 pg ml− 1.
Demographic and clinical characteristics at the baseline survey and at
the follow-up survey, when the cases and controls were assessed by
psychiatrists, were compared among the MDD, minDD, minDE with a
history of MDE (excluding minDE with a history of dysthymic disorder) and
control groups using the χ2-test and the one-way analyses of variance.
Compared characteristics included potential confounders, which were
found in previous epidemiologic studies44–46 and clinical studies.47,48 The
associations between these characteristics and serum BDNF levels were
examined with the analyses of variance or the Spearman’s correlation
coefficient. Serum BDNF levels at baseline were compared between each
of the three mood disorder groups and the control group by the analyses
of variance with Dunnet multiple comparison tests considering possible
confounders. To examine whether the changes of serum BDNF levels from
the baseline survey to the follow-up survey differed among the four
groups, BDNF levels at baseline and those at follow-up when the cases and
controls were identified were entered as dependent variables together in a
repeated mixed model with Scheffe multiple comparison tests. Mixed
analyses allowed us to use all available values without effects of missing
values.49 We performed all analyses with the software program SPSS
version 18.0 (SPSS, Chicago, IL, USA) and SAS version 9.2 (SAS Institute,
Cary, NC, USA).
The study was approved by the ethics committee of the Toho University
Faculty of Medicine (registration number 25106). Written informed consent
was obtained at the baseline survey and at the follow-up surveys.
RESULTS
The number of participants in the follow-up surveys was 729 in
2010 and 570 in 2012 (Table 1 and Supplementary Figures 1
and 2). Of the persons who had been screened as positive with the
DSBC, 111 had participated in the psychiatrists’ evaluation in 2010
or 2012. Of the persons who had been screened as negative, 40
from a convenient sample in 2010 and 122 from a consecutive
sample of 162 persons in 2012 had participated. Among the total
of 273 participants, psychiatrists identified 80 cases of mood
disorders developed during the 4-year follow-up period. Of the 9
persons who had minDE, only 1 person, who had a history of
dysthymic disorder, was excluded from the analyses. Finally,
incident cases were combined into three diagnostic groups: a
Table 1. Number of participants and incident cases of mood disorders
identified at psychiatrists’ assessments in 2010 and 2012 follow-up
surveys
2010 2012
Participants in main body of follow-up surveys 729 570
DSBC ⩾ 2 108 100
DSBC ⩽ 1 621 470
Participants in psychiatrists’ assessment 84 189
From all with DSBC ⩾ 2 44 67
A convenient sample with DSBC ⩽ 1 40
From a consecutive sample of 163 with DSBC ⩽ 1 122
Incident cases of mood disorders 22 58
Major depressive disorder 8 20
Current 2 8
Partial remission 2 4
Full remission 4 6
Under treatment 0 2
Minor depressive disordera 14 25
Current 13 24
Full remission 1 1
Minor depressive episode,b current 0 9
With history of major depressive episode 0 8
With history of dysthymic disorder 0 1
Dysthymic disorder, current 0 2
Double depression, current 0 1
Bipolar II disorder 0 1
Non-depressed controls 106
Abbreviation: DSBC, Depression Scale Basic Checklist. aMinor depressive
disorder was diagnosed according to the criteria sets for further study in
Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-
IV).41 bMinor depressive episode was defined as depression that meets the
criteria for minor depressive disorder except that there had never been a
major depressive episode or a dysthymic disorder.
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MDD group of 28 persons; a minDD group of 39 persons; and a
minDE with a history of MDE (referred to as ‘minDE with MDE
history’) group of 8 persons. These persons, except for 2 persons
with MDD who were being treated during follow-up, had not
received any antidepressant during the 4-year follow-up period.
Among them, 10 persons in the MDD group, 37 in the minDD
group and 8 in the minDE with MDE history group were in a
current episode. The control group consisted of 106 persons.
Table 2 shows demographic and clinical characteristics from the
follow-up surveys in 2010 or 2012, when cases and controls were
identified. There were significant associations between diagnostic
groups and (a) sports and exercise activity, (b) the time difference
between the baseline survey and the onset of current episodes
and (c) storage duration of sera between blood draws and BDNF
assays. In 5 of the 6 persons of the MDD group with a history of
MDE, the first episode had developed after an age of 65 years.
Among the characteristics listed in Table 2 (details not shown in
the table), a history of MDE, smoking and alcohol drinking were
related to serum BDNF levels; mean BDNF levels were higher in
persons without a history of MDE (11.5 (s.d. = 4.4) ng ml− 1) than in
persons with a history (6.9 (4.0), P= 0.036), in smokers (16.7 (8.8))
than in nonsmokers (11.0 (6.2), P= 0.030) and in persons who
drank 4 or fewer days per week (11.5 (6.3)) than in persons who
drank 5 or more days (6.9 (5.1), P= 0.020). The storage duration of
sera was correlated with BDNF levels; a person with longer storage
duration had a higher BDNF level (ρ= 0.181, P= 0.021).
Characteristics at baseline, except for the storage duration of
sera, did not differ among the four diagnostic groups (Table 3).
Among these characteristics (details not shown in Table 3), alcohol
drinking was related to serum BDNF levels (11.6 (s.d. = 6.4)
ng ml− 1 for persons who drank 4 days or less per week and 7.3
(4.5) for 5 days or more, P= 0.021). Mean BDNF levels differed
between whether a history of MDE was present (14.8 (3.5)) or
absent (12.9 (3.3), P= 0.044). The serum BDNF level at baseline did
not differ between the mood disorder groups and the control
group; after the effect of the storage duration of sera, alcohol
drinking and a history of MDE and the timing of blood drawing
(morning or afternoon) were controlled.
Mean serum BDNF levels at follow-up in cases that had not
been treated with any antidepressant but had fulfilled the
diagnostic criteria of current episodes for each mood disorder
were 7.3 (s.d. = 3.7) ng ml− 1 for MDD, 12.8 (5.9) for minDD and 6.8
(4.2) for minDE with MDE history (Figure 1). Mean serum BDNF
levels in other groups at follow-up were 11.4 (6.6) for control, 13.7
(3.7) for MDD in partial remission, 13.8 (7.8) for MDD in full
remission and 11.3 (12.0) for under treatment. Entered into a
repeated mixed model for dependent variables were as follows:
the BDNF values at follow-up of controls and persons with current
depression episodes but not in full remission, partial remission or
under treatment; and all available values of BDNF at baseline.
Entered into the model as confounders were the following:
alcohol drinking, timing of blood drawing and storage duration of
sera at baseline; the habits of smoking and drinking alcohol,
activity in sports or exercise, timing of blood drawing and storage
duration of sera at follow-up; time difference between baseline
survey and follow-up survey; the time difference between the
baseline survey and the onset of current episode; the history of
MDE; and age at psychiatrists’ assessments. After the effects of the
confounders were controlled, the interaction between time and
diagnostic groups was significant in the model (P= 0.0009). It is
only smoking at follow-up that was found to have a significant
fixed effect among the confounders in the model (P= 0.030).
Multiple comparisons of interactions between time and each pair
of the diagnostic groups showed that BDNF levels decreased more








with history of MDE (n= 8)
P-value
Age at psychiatrists’ assessments, years 81.8 (2.3) 80.5 (2.4) 81.5 (2.6) 81.6 (3.2) 0.066
MMSE at psychiatrists’ assessments, points 27.8 (2.0) 27.9 (1.9) 28.3 (2.1)c 27.3 (2.0) 0.457
Onset age of current episode of depression,
years
79.5 (2.5) 80.7 (2.7)c 80.6 (3.2) 0.208
Duration of illness,d months 11.3 (10.8) 11.1 (10.3)c 11.1 (4.6) 0.998
HAMD score,d points 15.7 (3.8) 9.3 (1.8) 10.3 (1.7) 0.000
Antidpressant use during follow-up period,
%
— 7.1e — —
Having history of major depressive episodes,
%
21.4 100.0
Antidepressant use in the previous MDE, % 3.6 —
Living alone, % 41.5 28.6 38.5 50.0 0.580
Smoker, % 5.7 — — 0.222
Drinking alcohol 5 days or more per week, % 9.4 3.6 2.6 — 0.337
Sports or exercise activity with 1 day or less
per week, %
74.5 67.9 87.2 37.5 0.021
Body mass index, kg/m2 22.6 (4.0) 21.3 (3.1) 21.5 (3.2) 23.2 (3.0) 0.165
History of heart diseases, % 17.0 28.6 20.5 28.6 0.529
Time difference between baseline survey
and onset of current episode, months
48.0 (0.0)f 27.8 (13.0) 29.1 (13.8)c 37.8 (4.5) 0.000
Blood drawing in the afternoon, % 50.9 53.6 51.3 87.5 0.256
Fasting at blood drawing, % 1.9 — 2.6 — 0.840
Storage duration of sera,d months 4.0 (0.0) 11.4 (15.6) 17.0 (17.9) 4.0 (0.0) 0.000
Abbreviations: HAMD, GRID–Hamilton Rating Scale for Depression; MDE, major depressive episode; MMSE, Mini-Mental State Examination. Mean values (s.d.)
were shown as long as % was not indicated in the first column. aMinor depressive disorder was diagnosed according to the criteria sets for further study in
Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV).41 bMinor depressive episode was defined as depression that meets the criteria for
minor depressive disorder except that there had never been a major depressive episode or a dysthymic disorder. cOne missing value. dDuration of illness, time
period between the beginning of the latest episode and the follow-up survey; storage duration of sera, time period between blood drawing and brain-derived
neurotrophic factor assay. Values for these items were shown for 10 persons with current episode of major depressive disorder, 37 persons with current
episode of minor depressive disorder and 8 persons with current episode of minor depressive episode with MDE history. eThey were the same persons who
were identified as being under treatment at follow-up. fTime of the 2012 follow-up were used instead of onset time of onset of current episode.
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over time in the MDD group and the minDE with MDE history
group than in the control group or minDD group (Figure 1). We
conducted another repeated mixed model as a post hoc analysis
to control further the effect of the history of MDE in the remaining
of 167 persons after excluding all 8 cases of minDE with MDE
history and 6 cases of MDD with the history. In the model, which
considered the same confounders as the first model except for
excluding the history of MDE, BDNF levels decreased more over
time in the MDD group without the history as compared with the
control group or minDD group (Figure 2).
DISCUSSION
Using incident cases and controls from a cohort in a 4-year
observation, we found that serum BDNF levels at baseline were
not lower in groups of MDD, minDD or minDE with MDE history








Minor depressive episodeb with history
of major depressive episode (n= 8)
P-value
Serum BDNF, ng ml− 1 12.6 (3.6) 13.9 (3.1)c 13.6 (2.6) 14.5 (3.2) 0.090
Age at baseline, years 77.9 (2.3) 77.0 (2.2) 78.3 (2.4) 77.6 (3.2) 0.209
Educational level at middle school
or less, %
22.6 25.0 25.6 37.5 0.811
Living alone, % 34.0 21.4 33.3 33.3 0.644
Smoker, % 6.6 3.6 2.6 0.0 0.643
Drinking alcohol 5 days or more
per week, %
8.5 17.9 5.1 12.5 0.336
Sports or exercise activity with
1 day or less per week, %
66.0 71.4 82.1 62.5 0.291
Body mass index, kg/m2 22.8 (3.6) 22.2 (2.6) 22.1 (2.8) 22.3 (3.0) 0.559
History of heart diseases, % 16.0 21.4 28.2 28.6 0.386
Prescribed steroid, % — — 2.6 — 0.300
Blood drawing in the afternoon, % 31.1 32.1 48.7 62.5 0.094
Fasting at blood drawing, % 0.9 — — — 0.868
Storage duration of sera, months 64.4 (0.5) 65.0 (0.6) 64.7 (0.5) 64.8 (0.7) 0.000
Abbreviation: BDNF, brain-derived neurotrophic factor. Mean values (s.d.) were shown as long as % was not indicated in the first column. Storage duration of
sera, time period between blood drawing and BDNF assay. aMinor depressive disorder was diagnosed according to the criteria sets for further study in
Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV).41 bMinor depressive episode was defined as depression that meets the criteria for






































Figure 1. Changes of serum brain-derived neurotrophic factor
(BDNF) levels from baseline to follow-up among the three incident
mood disorder groups and the control group. P-values were
calculated with Scheffe multiple comparisons of interactions
between time and each of the diagnostic groups in a repeated
mixed model. aMinor depressive disorder (minDD) was diagnosed
according to the criteria sets for further study in Diagnostic and
Statistical Manual of Mental Disorders, fourth edition.41 bMinor
depressive episode (minDE) was defined as depression that meets
the criteria for minDD except that there had never been a major
depressive episode (MDE) or a dysthymic disorder. cBetween minDE
with MDE history group and minDD group. dBetween major
depressive disorder (MDD) group and control group. eBetween































Figure 2. Changes of serum brain-derived neurotrophic factor
(BDNF) levels from baseline to follow-up among the two incident
mood disorder groups and the control group when excluding
persons with major depressive episode (MDE) history. P-values were
calculated with Scheffe multiple comparisons of interactions
between time and each of the diagnostic groups in a repeated
mixed model. aMinor depressive disorder (minDD) was diagnosed
according to the criteria sets for further study in Diagnostic and
Statistical Manual of Mental Disorders, fourth edition.41 bBetween
major depressive disorder (MDD) group and control group.
cBetween MDD and minDD groups.
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than in controls. In contrast, decreases in serum BDNF levels from
baseline to follow-up were greater in the MDD and the minDE
with MDE history groups than in the control group. Furthermore,
the decreases in BDNF levels from baseline to follow-up were
greater in the MDD group and the minDE with MDE history group
than in the minDD group.
To the best of our knowledge, we believe that the present study
is the first to show that serum BDNF levels before the
development of MDD and other mood disorders are not low
considering a history of MDE. Several cross-sectional studies
suggest that BDNF was a trait marker for depression and
correlated with neuroticism.30–34 In contrast, the first cohort
study36 did not necessarily show lower BDNF levels in an incident
MDD group at baseline, although the study did not eliminate the
effects of MDE history. The present longitudinal study, which
considered a history of MDE or excluded all cases with the history,
suggests that BDNF is not a trait marker for MDD or other types of
depression. Although not statistically significant, BDNF levels at
baseline seemed higher in the mood disorders groups than in the
control group. This difference might correspond to increased
BDNF being depressogenic in some animal studies.29,50,51
Instead of indicating that the serum BDNF level is a trait marker,
our finding that its baseline-to-follow-up decrease was signifi-
cantly greater in cases of MDD as compared with controls, even
after controlling the effects of a history of MDE, supports the
notion that it is a state marker of MDD. This notion has been
suggested by several cross-sectional and cohort studies,33,35,36
which did not consider the effect of a history of MDE. Duman
et al.,18,19 however, has postulated that stress decreases BDNF in
patients with MDD. Because the mean time of 28 months between
baseline and the developments of MDD in the present study
might be long enough for stress to decrease serum BDNF levels,
the level might have decreased before MDD developed. In
contrast, Bus et al.36 hypothesized that the decrease in BDNF
occurs some time after the onset of depression, as their cohort
study showed the baseline-to-follow-up decrease in chronic MDD
but not in incident MDD. Although our study showed the decrease
in incident MDD, frequent measurements of serum BDNF with
short interval from baseline through follow-up, unlike the
baseline-to-follow-up decrease, would be required to test the
hypothesis.
Our finding that changes in serum BDNF levels from baseline to
follow-up differed among the four groups is suggestive of the
pathophysiologic relationships of various subcategories of mood
disorders and of their classification. That the change in BDNF in
the minDD group was smaller than that in the MDD group and did
not differ from that in the control group suggests that the
pathophysiology of minDD differs from that of MDD. In contrast,
the changes in BDNF in both the MDD group and the minDE with
MDE history group were greater than those in the minDD group
and the control group. Furthermore, changes in BDNF levels in the
MDD group and minDE with MDE history group closely mirrored
one another. These findings suggest that MDD is pathophysiolo-
gically similar to minDE with MDE history. There have been
arguments about whether depression that does not fulfill the
criteria of MDD is a milder form of MDD or is a different category
of mood disorders.52 The results of the present study suggest that
minDD, a proposed category in DSM-IV, is a different category
from MDD and that minDE with MDE history is a milder form of
MDD. Differential diagnosis would be useful for selecting
treatment between MDD and minDD and between phenotypically
similar depressions, minDE with MDE history and minDD.53
The results of the present study are compelling for several
reasons in addition to the use of preserved sera from a large
number of subjects and a long observational period. First, the
case–control study in a cohort is less likely to have recall bias than
a standard case–control study. Second, obtaining numerous
variables with multidisciplinary surveys allowed the study to
consider the effects of confounders for any association between
depression and serum BDNF.44–48 Third, we could obtain cases
and controls from the same cohort. As our controls had been
shown to be a representative sample from participants in the 2012
follow-up survey,54 the controls seem less susceptible to selection
bias than controls in previous studies on serum BDNF, which were
not necessarily selected from a population from which cases were.
A limitation of the present study was that the cohort providing
the cases had low participation rates from the baseline survey to
the follow-up surveys; hence, only the less severe cases were
included in the analyses. This selection bias might also contribute
to the small number of cases with a history of MDE and made the
study mostly about the late onset of MDD. Furthermore, the only
subjects were old women. These limitations made the results
difficult to generalize. Another issue is recall bias, which
potentially occurs in psychiatric surveys depending on interviews
to identify previous episodes, even if the SCID, which improves the
validity and reliability of diagnoses, was used. Our old
subjects might not have recalled MDE from when they were
younger. Although the likelihood of recall bias appears similar in
cases and controls, the failure of recall in the minDD group
directly affects the number of cases of minDE with MDE history. If
some persons in the minDD group had actually had a history of
MDE and then been transferred to the minDE with MDE history
group, the serum BDNF levels during follow-up in this group
would likely have increased. Therefore, the decrease in BDNF
levels in this group might have been affected. We should
also consider the possibility that the cases from the old cohort
might include mild cognitive impairment or even dementia and,
therefore, that their BDNF levels became lower,55–57 while we
excluded persons with a low Mini-Mental State of Examination
score from the analyses.
The neurotrophin hypothesis, which postulates that BDNF is
involved in the development of MDD, has been supported by the
low BDNF levels found in postmortem brain studies and serum
studies.2–4 Serum studies are further expected to determine
whether low BDNF levels are a state or a trait marker.19 Our
epidemiologic approaches show that the serum BDNF level is not
a trait marker of MDD in old women. Instead, the longitudinal
decrease of BDNF levels in our data suggests that the serum BDNF
level is a state marker of MDD, leaving the possibility that BDNF
decreases several months before MDD develops. Furthermore, the
different patterns of changes in serum BDNF levels among the
diagnostic groups suggest that MDD has a pathophysiologic
relation, not to minDD, but probably to minDE with a MDE history.
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